136 related articles for article (PubMed ID: 37818704)
1. Obeticholic acid as a second-line treatment for low phospholipid-associated cholelithiasis syndrome.
Soret PA; Lemoinne S; Mallet M; Belkacem KB; Chazouillères O; Corpechot C
Aliment Pharmacol Ther; 2024 Jan; 59(1):113-117. PubMed ID: 37818704
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
3. Low phospholipid-associated cholelithiasis syndrome: A rare cause of acute pancreatitis that should not be neglected.
Gille N; Karila-Cohen P; Goujon G; Konstantinou D; Rekik S; Bécheur H; Pelletier AL
World J Hepatol; 2020 Jun; 12(6):312-322. PubMed ID: 32742573
[TBL] [Abstract][Full Text] [Related]
4. Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities.
Dong C; Condat B; Picon-Coste M; Chrétien Y; Potier P; Noblinski B; Arrivé L; Hauuy MP; Barbu V; Maftouh A; Gaouar F; Ben Belkacem K; Housset C; Poupon R; Zanditenas D; Chazouillères O; Corpechot C
JHEP Rep; 2021 Apr; 3(2):100201. PubMed ID: 33554096
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
7.
Biyoukar M; Corpechot C; El Mouhadi S; Chambenois E; Vanderbecq Q; Barbu V; Dong C; Lemoinne S; Tordjman M; Jomaah R; Chazouilleres O; Arrivé L
JHEP Rep; 2022 Nov; 4(11):100590. PubMed ID: 36277956
[TBL] [Abstract][Full Text] [Related]
8. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.
Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J
Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329
[TBL] [Abstract][Full Text] [Related]
13. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene.
Rosmorduc O; Poupon R
Orphanet J Rare Dis; 2007 Jun; 2():29. PubMed ID: 17562004
[TBL] [Abstract][Full Text] [Related]
14. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
15. Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition.
Li R; Hovingh MV; Koehorst M; de Blaauw P; Verkade HJ; de Boer JF; Kuipers F
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Aug; 1867(8):159163. PubMed ID: 35470044
[TBL] [Abstract][Full Text] [Related]
16. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
[TBL] [Abstract][Full Text] [Related]
17. Genetic Analysis of
Wang HH; Portincasa P; Liu M; Wang DQ
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741809
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
19. Low-Phospholipid Associated Cholelithiasis (LPAC) syndrome: A synthetic review.
Goubault P; Brunel T; Rode A; Bancel B; Mohkam K; Mabrut JY
J Visc Surg; 2019 Sep; 156(4):319-328. PubMed ID: 30922600
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
